arrow
E

Erica Moretti

Hospital of Prato
H指数:15
被引数:1,015

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing

使用浅细胞游离DNA甲基化测序进行敏感肿瘤检测和准确分型的计算框架

2026-02-030
OAAI
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer

通过体细胞拷贝数异常实现乳腺癌中ctDNA的敏感与精确检测

2025-03-080
OA
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
2024-12-010
PRE
Sensitive tumor detection, accurate quantification, and ER subtyping using low-pass methylome of liquid biopsy samples from patients (pts) with metastatic breast cancer (mBC)
2024-05-020
PRE
Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials
2023-03-010
PRE
Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial
2023-03-010
PRE
Circulating tumor cells, immunohistochemical subtypes, and genes mutation as prognostic markers in HER2 negative metastatic breast cancer patients candidates to chemotherapy
2023-03-010
PRE
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

ER阳性,HER2-negative晚期乳腺癌患者的循环肿瘤细胞和palbociclib治疗: TREnd试验的转化子研究结果

2021-03-2418
OAAI
Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial
2020-02-158
PRE
Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial
2019-07-010
PRE
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

TREnd试验中激素受体阳性和HER2-negative转移性乳腺癌的绝经后妇女接受palbociclib加或不加内分泌治疗后的临床结果

2019-05-2917
OAAI
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Palbociclib单药或联合内分泌治疗在疾病进展前接受雌激素受体阳性,HER2-negative转移性乳腺癌: 趋势试验

2018-08-0173
OAAI